TY - JOUR T1 - Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017 JF - The Journal of Rheumatology JO - J Rheumatol SP - 976 LP - 980 DO - 10.3899/jrheum.181066 VL - 46 IS - 8 AU - Toby O. Smith AU - Michael Mansfield AU - Gillian A. Hawker AU - David J. Hunter AU - Lyn M. March AU - Maarten Boers AU - Beverley J. Shea AU - Robin Christensen AU - Francis Guillemin AU - Caroline B. Terwee AU - Paula R. Williamson AU - Ewa M. Roos AU - Richard F. Loeser AU - Thomas J. Schnitzer AU - Margreet Kloppenburg AU - Tuhina Neogi AU - Christoph H. Ladel AU - Gurdyal Kalsi AU - Ulrike Kaiser AU - Thomas W. Buttel AU - Anne E. Ashford AU - Ali Mobasheri AU - Nigel K. Arden AU - Alan Tennant AU - Marc C. Hochberg AU - Maarten de Wit AU - Peter Tugwell AU - Philip G. Conaghan Y1 - 2019/08/01 UR - http://www.jrheum.org/content/46/8/976.abstract N2 - Objective. To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials.Methods. There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases.Results. COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient’s global assessment (48%) was the principal missing domain.Conclusion. Limited adoption of the COS domains indicates that further consideration to improve uptake is required. ER -